Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
122,541,881
-
Total 13F shares
-
101,272,913
-
Share change
-
+28,570,113
-
Total reported value
-
$327,119,655
-
Put/Call ratio
-
163%
-
Price per share
-
$3.23
-
Number of holders
-
130
-
Value change
-
+$79,248,549
-
Number of buys
-
84
-
Number of sells
-
65
Institutional Holders of Arcutis Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (ARQT) as of Q4 2023
As of 31 Dec 2023,
Arcutis Biotherapeutics, Inc. - Common Stock, $0.0001 par value per share (ARQT) was held by
130 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
101,272,913 shares.
The largest 10 holders included
JENNISON ASSOCIATES LLC, Frazier Life Sciences Management, L.P., SUVRETTA CAPITAL MANAGEMENT, LLC, Rubric Capital Management LP, Polar Capital Holdings Plc, MORGAN STANLEY, BlackRock Inc., VANGUARD GROUP INC, FRANKLIN RESOURCES INC, and Bain Capital Life Sciences Investors, LLC.
This page lists
130
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.